Erfahrungen mit „half-dose“ photodynamischer Therapie mittels Verteporfin bei Chorioretinopathia centralis serosa

The first antivascular endothelial growth factor (anti-VEGF) was developed as an anticancer drug for colonic carcinomas. Since then, anti-VEGFs have developed in scope and indications. They have revolutionized the treatment of exudative macular degeneration and have had a major impact on treatment of several other conditions. This has resulted in an increased number of patients seeking treatment with new treatment options and has had a considerable financial impact on health care resources. Anti-VEGFs have been used in the treatment of all age groups of the population ranging from infants where it is used for treatment of retinopathy of prematurity to the elderly where it is used in exudative macular eegeneration.

show abstract

Emerging roles for antiangiogenesis factors in management of ocular disease

Saeed

Gkaragkani²,

Ali³

2013

OPTH

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Erfahrungen mit „half-dose“ photodynamischer Therapie mittels Verteporfin bei Chorioretinopathia centralis serosa

Cited by 1 publication

References 34 publications

Emerging roles for antiangiogenesis factors in management of ocular disease

Emerging roles for antiangiogenesis factors in management of ocular disease

Contact Info

Product

Resources

About